VEGFA and choroidal neovascularization: Additionally, conbercept, another anti-VEGF agent known for its high affinity for both isoforms of VEGF-A and VEGF-B similar to aflibercept, has been authorized for the treatment of choroidal neovascularization (CNV) in China since 2013 and in Mongolia since 2020 [143].